2-sulfonylpyrimidines as privileged warheads for the development of S. aureus sortase A inhibitors

dc.contributor.authorBarthels, Fabian
dc.contributor.authorMeyr, Jessica
dc.contributor.authorHammerschmidt, Stefan J.
dc.contributor.authorMarciniak, Tessa
dc.contributor.authorRäder, Hans-Joachim
dc.contributor.authorZiebuhr, Wilma
dc.contributor.authorEngels, Bernd
dc.contributor.authorSchirmeister, Tanja
dc.date.accessioned2023-03-02T11:02:25Z
dc.date.available2023-03-02T11:02:25Z
dc.date.issued2021
dc.description.abstractStaphylococcus aureus is one of the most frequent causes of nosocomial and community-acquired infections, with emerging multiresistant isolates causing a significant burden to public health systems. We identified 2-sulfonylpyrimidines as a new class of potent inhibitors against S. aureus sortase A acting by covalent modification of the active site cysteine 184. Series of derivatives were synthesized to derive structure-activity relationship (SAR) with the most potent compounds displaying low micromolar KI values. Studies on the inhibition selectivity of homologous cysteine proteases showed that 2-sulfonylpyrimidines reacted efficiently with protonated cysteine residues as found in sortase A, though surprisingly, no reaction occurred with the more nucleophilic cysteine residue from imidazolinium-thiolate dyads of cathepsin-like proteases. By means of enzymatic and chemical kinetics as well as quantum chemical calculations, it could be rationalized that the SNAr reaction between protonated cysteine residues and 2-sulfonylpyrimidines proceeds in a concerted fashion, and the mechanism involves a ternary transition state with a conjugated base. Molecular docking and enzyme inhibition at variable pH values allowed us to hypothesize that in sortase A this base is represented by the catalytic histidine 120, which could be substantiated by QM model calculation with 4-methylimidazole as histidine analog.en_GB
dc.identifier.doihttp://doi.org/10.25358/openscience-8873
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/8889
dc.language.isoengde
dc.rightsCC-BY-4.0*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc570 Biowissenschaftende_DE
dc.subject.ddc570 Life sciencesen_GB
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.title2-sulfonylpyrimidines as privileged warheads for the development of S. aureus sortase A inhibitorsen_GB
dc.typeZeitschriftenaufsatzde
jgu.journal.titleFrontiers in molecular biosciencesde
jgu.journal.volume8de
jgu.organisation.departmentFB 09 Chemie, Pharmazie u. Geowissensch.de
jgu.organisation.nameJohannes Gutenberg-Universität Mainz
jgu.organisation.number7950
jgu.organisation.placeMainz
jgu.organisation.rorhttps://ror.org/023b0x485
jgu.pages.alternative804970de
jgu.publisher.doi10.3389/fmolb.2021.804970de
jgu.publisher.issn2296-889Xde
jgu.publisher.nameFrontiersde
jgu.publisher.placeLausannede
jgu.publisher.year2021
jgu.rights.accessrightsopenAccess
jgu.subject.ddccode570de
jgu.subject.ddccode610de
jgu.type.dinitypeArticleen_GB
jgu.type.resourceTextde
jgu.type.versionPublished versionde

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2sulfonylpyrimidines_as_privi-20230302115838017.pdf
Size:
2.46 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
3.57 KB
Format:
Item-specific license agreed upon to submission
Description: